The Ohio State University
ZIOPHARM Oncology Announces Dosing of First Patient in Phase 3 Study of ...MarketWatch (press release)Palifosfamide has demonstrated broad therapeutic activity, including effects against cancer stem cells, as well as good tolerability alone and in combination with various chemotherapeutics. MATISSE incorporates a novel, adaptive study design that ...
